

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application. Please amend claims 103 and 121 and add claims 124-127.

**Listing of Claims:**

Claims 1-94 (Cancelled)

95. (Previously Presented) A recombinant polypeptide comprising a pleiotrophin (PTN)-binding fragment of anaplastic lymphoma kinase (ALK), wherein the PTN-binding fragment consists of amino acid residues 368 to 447 of SEQ ID NO:2, and wherein said recombinant polypeptide does not comprise further regions of ALK.

96. (Previously Presented) The polypeptide of claim 95, wherein said polypeptide is soluble.

97-98. (Cancelled)

99. (Previously Presented) The polypeptide of claim 95 bound to PTN.

100. (Previously Presented) The polypeptide of claim 95 immobilized on a surface.

101. (Previously Presented) A composition comprising the polypeptide of claim 95, further comprising a pharmaceutically acceptable carrier.

102. (Cancelled)

103. (Currently Amended) The composition of claim 101, wherein said polypeptide is present in said composition in a therapeutically effective amount for the stimulation of desired cell proliferation.

104. (Previously Presented) The composition of claim 101, further comprising PTN.

105. (Previously Presented) The composition of claim 101, further comprising PTN and a test substance that blocks the binding of PTN with ALK.

106. (Withdrawn) A method of screening the ability of a test substance to block binding of PTN with ALK, comprising comparing a measurement of the binding of PTN with the polypeptide of claim 95 obtained in the presence of the substance, with a control measurement to obtain a value.

107. (Withdrawn) The method of claim 106, wherein said control measurement is the measurement of binding of PTN with said polypeptide obtained in the absence of said substance.

108. (Withdrawn) A method of screening the ability of a test substance to block binding of PTN with ALK, comprising:

obtaining a first measurement of the binding of PTN with the polypeptide of claim 95;  
obtaining a second measurement of the binding of PTN with the polypeptide of claim 95, wherein said first measurement is performed in the absence of the substance and said second measurement is performed in the presence of said substance; and comparing said first measurement to said second measurement to obtain a value.

109. (Withdrawn) A method of screening the ability of a test substance to block binding of PTN with ALK, comprising:

incubating the substance with PTN and the polypeptide of claim 95 under conditions suitable for binding of PTN to said polypeptide; obtaining a measurement of the binding; and comparing the measurement of said binding with a control measurement, to obtain a value.

110. (Withdrawn) The method of claim 109, wherein the control measurement is the measurement of binding of PTN with the polypeptide of claim 95 obtained in the absence of said substance.
111. (Withdrawn) A method for inhibiting binding of PTN with ALK, comprising contacting PTN with the polypeptide of claim 95 in the presence of ALK and under conditions suitable for binding of PTN with said polypeptide.
112. (Withdrawn) The method of claim 111, wherein ALK is expressed by a cell.
113. (Withdrawn) The method of claim 112, wherein said cell is a tumor cell.
114. (Withdrawn) The method of claim 111 wherein said ALK is immobilized to a surface.
115. (Withdrawn) A method for blocking ALK activity, comprising contacting a cell expressing ALK with the polypeptide of claim 95 in the presence of PTN and under conditions suitable to inhibit binding of PTN with said ALK, thereby blocking ALK activity.
116. (Withdrawn) A method for blocking ALK activity, comprising contacting ALK with the polypeptide of claim 95 in the presence of PTN and under conditions suitable to inhibit binding of PTN with said ALK, thereby blocking ALK activity.
117. (Withdrawn) The method of claim 115, wherein said cell is a tumor cell.
118. (Withdrawn) The method of claim 116, wherein said ALK is immobilized on a surface.
119. (Previously Presented) The recombinant polypeptide of claim 95, further comprising an Fc domain.

120. (Previously Presented) A composition comprising the peptide of claim 119, further comprising a pharmaceutically acceptable carrier.

121. (Currently Amended) The composition of claim 120, wherein said peptide is present in said composition in a therapeutically effective amount for the stimulation of desired cell proliferation.

122. (Previously Presented) The composition of claim 120, further comprising PTN.

123. (Previously Presented) The composition of claim 120, further comprising PTN and a test substance that blocks the binding of PTN with ALK.

124. (New) The composition of claim 101, wherein said polypeptide is present in said composition in a therapeutically effective amount for the prevention of cell proliferation that is not desired.

125. (New) The composition of claim 120, wherein said peptide is present in said composition in a therapeutically effective amount for the prevention of cell proliferation that is not desired.

126. (New) The composition of claim 101, wherein said polypeptide is present in said composition in a therapeutically effective amount for the induction of apoptosis.

127. (New) The composition of claim 120, wherein said peptide is present in said composition in a therapeutically effective amount for the induction of apoptosis.